Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection. Liu CH, Cheng PN, Fang YJ, Chen CY, et al. J Hepatol 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024.

Read + Share

Amedeo Smart

Independent Medical Education

Liu CH, Cheng PN, Fang YJ, Chen CY, et al. Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection. J Hepatol 2024 Oct 3:S0168-8278(24)02578-9. doi: 10.1016/j.jhep.2024.
PMID: 39368711